Phenylketonuria Treatment Market size was valued at USD 794.16 million in 2024 and is set to exceed USD 1.98 billion by 2037, expanding at over 7.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of phenylketonuria treatment is evaluated at USD 843.44 million.
The growth of the market can be attributed to the rising prevalence of phenylketonuria globally and high incidence rate of the disorder in some emerging countries such as Turkey. Further, the increasing government initiatives in order to increase awareness & knowledge towards market, along with the surge in the mergers and acquisitions between different key players for the development of new drugs is propelling demand for phenylketonuria treatment are anticipated to drive the market growth. Moreover, rising research activities in the field of biotechnology and genomics is also anticipated to contribute to the growth of the market in the coming years.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.3% |
|
Base Year Market Size (2024) |
USD 794.16 million |
|
Forecast Year Market Size (2037) |
USD 1.98 billion |
|
Regional Scope |
|
The market is segmented on the basis of drug type into Palynziq, Kuvan, SYNB1618 and others. Among these segments, the Kuvan drug segment is estimated to capture the largest market share in the year 2021. Kuvan drug contains the oral pharmaceutical formulation BH4, which is known to stimulate the activity of phenylalanine hydroxylase enzyme to metabolize phenylalanine into tyrosine.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Route of Administration |
|
|
By End Users |
|
Geographically, the phenylketonuria treatment market is segmented into five major region including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Among the market in these regions, North America industry is likely to hold largest revenue share by 2037, attributed to rising research and development activities for novel drugs, coupled with favourable government regulations for the treatment of phenylketonuria. In addition, improvements in healthcare infrastructure in the region along with growing cases of new-born suffering from the disorder is also projected to foster the market growth.
On the other hand, the market in the Asia Pacific is anticipated to foresee significant growth on account of the rising population in emerging nations and growing awareness for the treatment of phenylketonuria. Moreover, progress in the economies along with several screening programs in the region is also estimated to accelerate the market growth over the forecast period.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?